Gastrointestinal effects of eating quinoa (Chenopodium quinoa Willd.) in celiac patients

• Published in: The American journal of gastroenterology Vol. 109; no. 2; pp. 270 - 278
• Main Authors: Zevallos, Victor F, Herencia, L Irene, Chang, Fuju, Donnelly, Suzanne, Ellis, H Julia, Ciclitira, Paul J
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.02.2014
• Subjects: Adult; Aged; Aged, 80 and over; Celiac Disease - diet therapy; Celiac Disease - drug therapy; Celiac Disease - immunology; Chenopodium quinoa; Cohort Studies; Combined Modality Therapy; Diet, Gluten-Free - methods; Female; Follow-Up Studies; Gastroenterology; Humans; Intestinal Mucosa - drug effects; Intestinal Mucosa - pathology; Male; Middle Aged; Patients; Phytotherapy - methods; Plant Preparations - administration & dosage; Prospective Studies; Safety; Time Factors; Treatment Outcome
• ISSN: 0002-9270; 1572-0241
• DOI: 10.1038/ajg.2013.431

Celiac disease is an enteropathy triggered by dietary gluten found in wheat, rye, and barley. Treatment involves a strict gluten-free diet (GFD). Quinoa is a highly nutritive plant from the Andes that has been recommended as part of a GFD. However, in-vitro data suggested that quinoa prolamins can stimulate innate and adaptive immune responses in celiac patients. Therefore, we aimed to evaluate the in-vivo effects of eating quinoa in adult celiac patients. Nineteen treated celiac patients consumed 50 g of quinoa every day for 6 weeks as part of their usual GFD. We evaluated diet, serology, and gastrointestinal parameters. Furthermore, we carried out detail histological assessment of 10 patients before and after eating quinoa. Gastrointestinal parameters were normal. The ratio of villus height to crypt depth improved from slightly below normal values (2.8:1) to normal levels (3:1), surface-enterocyte cell height improved from 28.76 to 29.77 μm and the number of intra-epithelial lymphocytes per 100 enterocytes decreased from 30.3 to 29.7. Median values for all the blood tests remained within normal ranges, although total cholesterol (n=19) decreased from 4.6 to 4.3 mmol/l, low-density lipoprotein decreased from 2.46 to 2.45 mmol/l, high-density lipoprotein decreased from 1.8 to 1.68 mmol/l and triglycerides decreased from 0.80 to 0.79 mmol/l. Addition of quinoa to the GFD of celiac patients was well tolerated and did not exacerbate the condition. There was a positive trend toward improved histological and serological parameters, particularly a mild hypocholesterolemic effect. Overall, this is the first clinical data suggesting that daily 50 g of quinoa for 6 weeks can be safely tolerated by celiac patients. However, further studies are needed to determine the long-term effects of quinoa consumption.